Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
- Conditions
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Sansum Diabetes Research Institute
- Target Recruit Count
- 25
- Registration Number
- NCT03668808
- Locations
- 🇺🇸
inControl Diabetes Center, Honolulu, Hawaii, United States
🇺🇸Sansum Diabetes Research Institute, Santa Barbara, California, United States
Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin
- Conditions
- Interventions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 32
- Registration Number
- NCT03400501
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2
- Conditions
- Interventions
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 15
- Registration Number
- NCT03387787
- Locations
- 🇨🇭
Division of Endocrinology, Diabetes, Clinical Nutrition & Metabolism, University Hospital Berne, Switzerland, Berne, Switzerland
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 225
- Registration Number
- NCT03377699
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT03292185
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1264
- Registration Number
- NCT03268005
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Vinnytsia, Ukraine
A Study of LY900014 in Participants With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1392
- Registration Number
- NCT03214367
- Locations
- 🇺🇸
Valley Endocrine, Fresno, Fresno, California, United States
🇺🇸Physicians East, Greenville, North Carolina, United States
🇺🇸Diabetes and Endocrine Associates, La Mesa, California, United States
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 933
- Registration Number
- NCT03214380
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Aventiv Research, Columbus, Ohio, United States
🇺🇸Dallas Diabetes Endocrine Center, Dallas, Texas, United States
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
- Conditions
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 453
- Registration Number
- NCT03175120
- Locations
- 🇭🇰
Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
- Conditions
- Interventions
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 720
- Registration Number
- NCT03172494
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Fuzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.